Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
46.06
+0.98 (2.17%)
Apr 24, 2026, 2:36 PM EDT - Market open
Corcept Therapeutics Revenue
In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth. Corcept Therapeutics had revenue of $202.13M in the quarter ending December 31, 2025, with 11.12% growth.
Revenue (ttm)
$761.41M
Revenue Growth
+12.79%
P/S Ratio
6.46
Revenue / Employee
$1,043,023
Employees
730
Market Cap
4.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.03B |
| Apellis Pharmaceuticals | 1.00B |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| Mirum Pharmaceuticals | 521.31M |
| Ligand Pharmaceuticals | 268.09M |
| Xenon Pharmaceuticals | 7.50M |
| CRISPR Therapeutics AG | 3.51M |
CORT News
- 22 hours ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 3 days ago - Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 - Business Wire
- 4 days ago - CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st - GlobeNewsWire
- 13 days ago - Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 27 days ago - Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session - Business Wire
- 4 weeks ago - Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
- 4 weeks ago - FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 4 weeks ago - Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately - PRNewsWire